Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRC014
MIFTS: 59

Sarcoma

Categories: Bone diseases, Cancer diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Sarcoma

About this section

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 11 28 53 5 43 14 16 71 75
Connective and Soft Tissue Neoplasm 11
Tumor of Soft Tissue and Skeleton 11
Sarcoma - Category 71
Sarcomas 14

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:1115
ICD9CM 34 171.9
MeSH 43 D012509
SNOMED-CT 68 93765001
ICD10 31 C49
UMLS 71 C0153519 C1261473 C1299262
Sources

Summaries for Sarcoma

About this section

Disease Ontology: 11 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary: Sarcoma, also known as connective and soft tissue neoplasm, is related to ewing sarcoma and sarcoma, synovial. An important gene associated with Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Malignant pleural mesothelioma. The drugs Lopinavir and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotypes are Increased telomerase activity and neoplasm

Wikipedia: 75 A sarcoma is a malignant tumor, a type of cancer that arises from transformed cells of mesenchymal... more...
Sources

Related Diseases for Sarcoma

About this section

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2568)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 33.9 TP53 SSX2 SSX1 SS18 KIT FLI1
2 sarcoma, synovial 33.6 SSX4 SSX2 SSX1 SS18 KIT FLI1
3 alveolar soft part sarcoma 33.5 SSX2 SSX1 SS18 KIT EWSR1 ASPSCR1
4 endometrial stromal sarcoma 33.4 TP53 SSX2 SS18 KIT EWSR1
5 epithelioid sarcoma 33.3 SSX2 SS18 FLI1 EWSR1
6 clear cell sarcoma 33.3 SSX2 SS18 KIT EWSR1
7 spindle cell sarcoma 33.2 TP53 SSX2 SSX1 SS18 KIT EWSR1
8 malignant fibrous histiocytoma 33.1 TP53 KIT EWSR1
9 heart sarcoma 33.0 SSX2 SSX1 SS18 KIT
10 ewing sarcoma of bone 33.0 FLI1 FES EWSR1
11 osteogenic sarcoma 33.0 TP53 JUN HOTAIR FAU CHEK2
12 rhabdoid cancer 32.9 TP53 SSX2 SS18 EWSR1
13 kidney sarcoma 32.9 SSX2 SSX1 SS18 EWSR1
14 monophasic synovial sarcoma 32.8 SSX4 SSX2 SSX1 SS18 EWSR1
15 small intestinal sarcoma 32.8 KIT EWSR1
16 biphasic synovial sarcoma 32.8 SSX4 SSX2 SSX1 SS18 EWSR1
17 lung sarcoma 32.7 SSX2 SSX1 SS18 EWSR1
18 dermatofibrosarcoma protuberans 32.7 SSX2 SSX1 SS18 KIT EWSR1
19 spindle cell synovial sarcoma 32.7 SSX4 SSX2 SSX1 SS18
20 fibrosarcoma 32.7 TP53 KIT JUN EWSR1
21 epithelioid cell synovial sarcoma 32.7 SSX2 SSX1 SS18 EWSR1
22 gastrointestinal stromal tumor 32.7 TP53 SSX2 SS18 SRC KIT HRAS
23 meninges sarcoma 32.7 SSX2 SS18
24 muscle cancer 32.6 TP53 SSX2 SSX1 SS18 KIT HRAS
25 embryonal rhabdomyosarcoma 32.6 TP53 SSX2 SS18 HRAS EWSR1
26 leiomyosarcoma 32.6 TP53 KIT CHEK2
27 breast sarcoma 32.5 TP53 KIT
28 liver angiosarcoma 32.5 TP53 HRAS
29 uterine carcinosarcoma 32.5 TP53 KIT HRAS
30 meningioma, familial 32.5 TP53 SRC KIT HRAS EWSR1
31 carcinosarcoma 32.5 TP53 KIT HRAS
32 desmoplastic small round cell tumor 32.5 SSX2 SSX1 SS18 EWSR1
33 hemangiopericytoma, malignant 32.4 SSX2 SSX1 KIT
34 myxoid liposarcoma 32.4 TP53 SSX4 SSX2 SSX1 SS18 KIT
35 dedifferentiated liposarcoma 32.4 TP53 SSX2 SSX1 SS18 KIT EWSR1
36 rhabdomyosarcoma 32.4 TP53 SSX2 SSX1 KIT HRAS FLI1
37 myxofibrosarcoma 32.3 TP53 SSX2 SSX1 SS18 KIT EWSR1
38 chondrosarcoma, extraskeletal myxoid 32.3 SSX2 SSX1 SS18 KIT EWSR1
39 bone angioendothelial sarcoma 32.3 SSX4 SSX1
40 askin's tumor 32.2 FLI1 EWSR1
41 extraosseous osteosarcoma 32.1 SSX1 KIT
42 sarcomatosis 32.1 KIT EWSR1
43 mesenchymal cell neoplasm 32.1 TP53 SSX2 SS18 KIT EWSR1
44 connective tissue disease 32.1 TP53 SRC KIT JUN HRAS EWSR1
45 small cell osteogenic sarcoma 32.1 FLI1 EWSR1
46 localized osteosarcoma 32.0 TP53 EWSR1
47 leukemia, acute myeloid 31.8 TP53 SRC KIT JUN HRAS HOTAIR
48 rhabdomyosarcoma 2 31.8 TP53 SSX2 SSX1 SS18 KIT EWSR1
49 connective tissue benign neoplasm 31.8 TP53 KIT EWSR1
50 wilms tumor 1 31.7 TP53 KIT HRAS EWSR1 CHEK2

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma
Sources

Symptoms & Phenotypes for Sarcoma

About this section

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased telomerase activity GR00156-A 8.32 SRC

MGI Mouse Phenotypes related to Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.61 CHEK2 ERG EWSR1 FES FLI1 HRAS
2 endocrine/exocrine gland MP:0005379 9.32 CHEK2 ERG EWSR1 FES FLI1 HRAS
Sources

Drugs & Therapeutics for Sarcoma

About this section

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 536)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lopinavir Approved Phase 4 192725-17-0 92727
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
4
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
5
Bleomycin Approved, Investigational Phase 4 9041-93-4, 11056-06-7 5360373
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 135413536
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
10
Tranexamic acid Approved Phase 4 1197-18-8 5526
11
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
12
Reviparin Approved, Investigational Phase 4 9041-08-1
13
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Reverse Transcriptase Inhibitors Phase 4
17 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
18 Stavudine, lamivudine, nevirapine drug combination Phase 4
19 Antifibrinolytic Agents Phase 4
20 Hemostatics Phase 4
21 Coagulants Phase 4
22 Calcineurin Inhibitors Phase 4
23 Antipyretics Phase 4
24 Platelet Aggregation Inhibitors Phase 4
25 Heparin, Low-Molecular-Weight Phase 4
26
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
27
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
28
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
29
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5, 188062-50-2 441300
30
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
31
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
32
Olaparib Approved Phase 3 763113-22-0 23725625
33
Panitumumab Approved, Investigational Phase 3 339177-26-3
34
Trifluridine Approved, Investigational Phase 3 70-00-8 6256
35
Trametinib Approved Phase 3 871700-17-3 11707110
36
Ceritinib Approved Phase 3 1032900-25-6 57379345
37
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908
38
Futibatinib Approved, Investigational Phase 3 1448169-71-8 71621331
39
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760
40
Plasminogen Approved Phase 3 9001-91-6
41
Ifosfamide Approved Phase 3 3778-73-2 3690
42
Daunorubicin Approved Phase 3 20830-81-3 30323
43
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
44
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239
45 Grape Approved Phase 3
46 Cranberry Approved, Investigational Phase 3
47
Epirubicin Approved Phase 3 56420-45-2 41867
48
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
49
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
50
Cytarabine Approved, Investigational Phase 3 147-94-4 6253

Interventional clinical trials:

(show top 50) (show all 1694)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Completed NCT04223583 Phase 4 Anlotinib Hydrochloride
5 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Completed NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
6 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
7 An Open Label, Single Centre, Single Arm, Prospective Feasibility Study Evaluating the Effectiveness of Near-infrared Fluorescence (NIRF) Using Indo-cyanine Green (ICG) in Minimally Invasive Paediatric Oncology Surgery (MIS) Recruiting NCT04854018 Phase 4 Indocyanine green
8 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Recruiting NCT04033081 Phase 4
10 Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial Recruiting NCT04347122 Phase 4 Tranexamic Acid (TXA)
11 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
12 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
13 Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial Recruiting NCT04448873 Phase 4 Sirolimus
14 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
15 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial Terminated NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
16 Assessment of the Effect of a Co-treatment With GnRH Analogs on the Ovarian Reserve in Adolescents and Young Women Treated With Alkylating Agents for Cancer Unknown status NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
17 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
18 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
19 Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma Unknown status NCT02565498 Phase 3
20 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
21 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
22 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
23 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
24 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
25 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
26 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
27 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
28 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
29 Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
30 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
31 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
32 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
33 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
34 Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma. Completed NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
35 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
36 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
37 A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
38 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
39 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
40 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
41 Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma Completed NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
42 Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
43 Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
44 Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
45 A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 Completed NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
46 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
47 A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies. Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
48 A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
49 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
50 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Cochrane evidence based reviews: sarcoma

Sources

Genetic Tests for Sarcoma

About this section

Genetic tests related to Sarcoma:

# Genetic test Affiliating Genes
1 Sarcoma 28
Sources

Anatomical Context for Sarcoma

About this section

Organs/tissues related to Sarcoma:

MalaCards : Bone, Breast, Prostate, T Cells, Uterus, Bone Marrow, Myeloid
Sources

Publications for Sarcoma

About this section

Articles related to Sarcoma:

(show top 50) (show all 50103)
# Title Authors PMID Year
1
Nonsense-mediated mRNA decay: terminating erroneous gene expression. 5
15145354 2004
2
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. 53 62
20166202 2010
3
Targets for cancer therapy in childhood sarcomas. 53 62
20223596 2010
4
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. 53 62
20081808 2010
5
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. 53 62
20526094 2010
6
Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. 53 62
20186824 2010
7
Sarcoma of the cervical spine after radiation treatment for thyroid cancer. 53 62
20375775 2010
8
Molecular classification of soft tissue sarcomas and its clinical applications. 53 62
20490332 2010
9
Translating gene expression into clinical care: sarcomas as a paradigm. 53 62
20194847 2010
10
Werner syndrome gene variants in human sarcomas. 53 62
19824023 2010
11
[A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. 53 62
20168062 2010
12
IGF-1R targeted treatment of sarcoma. 53 62
20036195 2010
13
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. 53 62
20031388 2010
14
ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases. 53 62
20306994 2010
15
Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. 53 62
19376842 2010
16
Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. 53 62
19577358 2010
17
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. 53 62
19820690 2009
18
v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. 53 62
19955937 2009
19
Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. 53 62
19540561 2009
20
Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. 53 62
19837262 2009
21
Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. 53 62
19647855 2009
22
An overview of small-molecule inhibitors of VEGFR signaling. 53 62
19736552 2009
23
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. 53 62
19789339 2009
24
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. 53 62
19817894 2009
25
Endosialin: from vascular target to biomarker for human sarcomas. 53 62
20477527 2009
26
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. 53 62
19825800 2009
27
WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. 53 62
19357702 2009
28
Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. 53 62
19532136 2009
29
Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. 53 62
19737974 2009
30
Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. 53 62
19664491 2009
31
A case of histiocytic sarcoma diagnosed by bone marrow biopsy in a patient suffering from fever for 8 months. 53 62
19726888 2009
32
Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma. 53 62
19480930 2009
33
Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. 53 62
19408047 2009
34
Targeting IGF-1R in the treatment of sarcomas: past, present and future. 53 62
19617179 2009
35
Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. 53 62
19383820 2009
36
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. 53 62
19366796 2009
37
The insulin-like growth factor system and sarcomas. 53 62
19148905 2009
38
IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. 53 62
19155307 2009
39
Low-grade fibromyxoid sarcoma versus fibromatosis: a comparative study of clinicopathological and immunohistochemical features. 53 62
19021197 2009
40
Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas. 53 62
18997735 2009
41
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. 53 62
18855347 2008
42
Expression analysis of apoptosis-related markers TP53, BCL-2, BAX and c-MYC in female genital tract sarcomas. 53 62
19114327 2008
43
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. 53 62
19010839 2008
44
Targeting sarcomas: therapeutic targets and their rational. 53 62
19013896 2008
45
Association of HDM2 transcript levels with age of onset and prognosis in soft tissue sarcomas. 53 62
18922973 2008
46
SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. 53 62
18580682 2008
47
[Correlation of telomere length and the expression of its regulating proteins in mesenchymal sarcomas]. 53 62
18677381 2008
48
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 53 62
18500263 2008
49
New targets for therapy of sarcoma. 53 62
18525335 2008
50
The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. 53 62
18620564 2008
Sources

Variations for Sarcoma

About this section

ClinVar genetic disease variations for Sarcoma:

5 (show all 16)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHEK2 NM_007194.4(CHEK2):c.341G>A (p.Trp114Ter) SNV Pathogenic
 560005 rs1555927374 GRCh37: 22:29121334-29121334
GRCh38: 22:28725346-28725346
2 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic
 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
3 MSH2 NM_000251.3(MSH2):c.128A>G (p.Tyr43Cys) SNV Uncertain Significance
 90619 rs17217723 GRCh37: 2:47630458-47630458
GRCh38: 2:47403319-47403319
4 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Not Provided
 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
5 TP53 NM_000546.6(TP53):c.448_459del (p.Thr150_Pro153del) DEL Not Provided
 133282 rs137852790 GRCh37: 17:7578471-7578482
GRCh38: 17:7675153-7675164
6 TP53 NM_000546.6(TP53):c.450_459del (p.Pro151fs) DEL Not Provided
 133283 rs137852791 GRCh37: 17:7578471-7578480
GRCh38: 17:7675153-7675162
7 TP53 NM_000546.6(TP53):c.886C>T (p.His296Tyr) SNV Not Provided
 132973 rs672601296 GRCh37: 17:7577052-7577052
GRCh38: 17:7673734-7673734
8 TP53 NM_000546.6(TP53):c.969G>A (p.Leu323=) SNV Not Provided
 132974 rs672601297 GRCh37: 17:7576877-7576877
GRCh38: 17:7673559-7673559
9 TP53 NM_000546.6(TP53):c.460G>A (p.Gly154Ser) SNV Not Provided
 133284 rs137852789 GRCh37: 17:7578470-7578470
GRCh38: 17:7675152-7675152
10 FGFR3 NM_000142.5(FGFR3):c.1887C>T (p.Asn629=) SNV Not Provided
 132957 rs104886004 GRCh37: 4:1807828-1807828
GRCh38: 4:1806101-1806101
11 FGFR3 NM_000142.5(FGFR3):c.1908C>G (p.Phe636Leu) SNV Not Provided
 132958 rs104886005 GRCh37: 4:1807849-1807849
GRCh38: 4:1806122-1806122
12 FGFR3 NM_000142.5(FGFR3):c.1935C>T (p.Leu645=) SNV Not Provided
 132959 rs104886006 GRCh37: 4:1807876-1807876
GRCh38: 4:1806149-1806149
13 PIK3CA NM_006218.2:c.1821+51A>T SNV Not Provided
 132966 GRCh37:
GRCh38:
14 FGFR3 NM_000142.5(FGFR3):c.2135G>A (p.Arg712His) SNV Not Provided
 132968 rs104886024 GRCh37: 4:1808377-1808377
GRCh38: 4:1806650-1806650
15 KRAS NM_033360.4(KRAS):c.216G>A (p.Met72Ile) SNV Not Provided
 132970 rs104886028 GRCh37: 12:25380242-25380242
GRCh38: 12:25227308-25227308
16 KRAS NM_033360.4(KRAS):c.219G>A (p.Arg73=) SNV Not Provided
 132971 rs104886027 GRCh37: 12:25380239-25380239
GRCh38: 12:25227305-25227305
Sources

Expression for Sarcoma

About this section
Search GEO for disease gene expression data for Sarcoma.
Sources

Pathways for Sarcoma

About this section

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 74
Show member pathways
 12.57 HRAS JUN KIT SRC TP53
2
Malignant pleural mesothelioma 74
12.53 TP53 SRC KIT JUN HRAS
3
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.37 TP53 SRC JUN HRAS
4
Development EGFR signaling pathway 22
Show member pathways
 12.37 TP53 SRC JUN HRAS
5
Breast cancer pathway 74
Show member pathways
 12.36 TP53 KIT JUN HRAS
6
NF-kappaB Pathway 70
Show member pathways
 12.34 TP53 JUN HRAS CHEK2
7
Integrated breast cancer pathway 74
11.91 CHEK2 FAU JUN TP53
8
DNA damage response (only ATM dependent) 74
11.82 TP53 JUN HRAS
9
ATM Pathway 64
Show member pathways
 11.71 CHEK2 JUN TP53
10
Thyroid hormones production and peripheral downstream signaling effects 74
11.71 HRAS SRC TP53
11
Development EPO-induced Jak-STAT pathway 22
Show member pathways
 11.69 SRC KIT HRAS FES
12
VEGF Pathway (Tocris) 70
Show member pathways
 11.68 KIT JUN HRAS
13
MAPK Signaling: Oxidative Stress 65
11.67 TP53 SRC JUN
14
RET signaling 66
Show member pathways
 11.65 SRC JUN HRAS
15
Gastrin signaling pathway 74
11.61 SRC KIT JUN HRAS
16
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) 61
11.6 SRC JUN HRAS
17
Agrin Interactions at Neuromuscular Junction 64
11.5 SRC JUN HRAS
18
Senescence and autophagy in cancer 74
11.48 TP53 SRC JUN HRAS
19
Proteolysis Putative SUMO-1 pathway 22
Show member pathways
 11.44 TP53 JUN CHEK2
20
Netrin-UNC5B signaling pathway 74
11.4 TP53 SRC JUN
21
LPA receptor mediated events 61
11.34 SRC JUN HRAS
22
Signal transduction_JNK pathway 22
11.3 TP53 JUN HRAS
23
Interleukin-11 signaling pathway 74
11.28 SRC HRAS FES
24
Signaling by SCF-KIT 66
Show member pathways
 11.25 SRC KIT HRAS FES
25
Transcription_Transcription factor Tubby signaling pathways 22
11.23 TP53 JUN HRAS
26
Bladder cancer 74
11.18 TP53 SRC HRAS
27
Endothelins 61
11.05 SRC JUN HRAS
28
PLK3 signaling events 61
10.34 TP53 CHEK2
29
MNAR-PELP1 and Estrogen Receptor Interaction 64
10.16 SRC JUN HRAS
Sources

GO Terms for Sarcoma

About this section

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of DNA-templated transcription GO:0006355 9.8 TP53 SSX4 SSX2 SSX1 JUN FLI1
2 cellular response to gamma radiation GO:0071480 9.63 TP53 HRAS CHEK2
3 positive regulation of protein modification process GO:0031401 9.43 KIT ASPSCR1
4 regulation of cell population proliferation GO:0042127 9.28 TP53 KIT JUN HRAS FES
Sources

Sources for Sarcoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....